BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15164875)

  • 1. Basis and importance of Src as a target in cancer.
    Levin VA
    Cancer Treat Res; 2004; 119():89-119. PubMed ID: 15164875
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic targeting of the receptor tyrosine kinase Met.
    Sattler M; Ma PC; Salgia R
    Cancer Treat Res; 2004; 119():121-38. PubMed ID: 15164876
    [No Abstract]   [Full Text] [Related]  

  • 3. Src inhibitors: genomics to therapeutics.
    Sawyer T; Boyce B; Dalgarno D; Iuliucci J
    Expert Opin Investig Drugs; 2001 Jul; 10(7):1327-44. PubMed ID: 11772255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diflomotecan. Ipsen.
    Osheroff N
    IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
    [No Abstract]   [Full Text] [Related]  

  • 5. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy.
    Johnson FM; Gallick GE
    Anticancer Agents Med Chem; 2007 Nov; 7(6):651-9. PubMed ID: 18045060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SRC family kinases as potential therapeutic targets for malignancies and immunological disorders.
    Benati D; Baldari CT
    Curr Med Chem; 2008; 15(12):1154-65. PubMed ID: 18473810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Src: regulation, role in human carcinogenesis and pharmacological inhibitors.
    Tsygankov AY; Shore SK
    Curr Pharm Des; 2004; 10(15):1745-56. PubMed ID: 15180537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of targeted interference with Src-mediated signal transduction events.
    Ly QP; Yeatman TJ
    Recent Results Cancer Res; 2007; 172():169-88. PubMed ID: 17607941
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New phosphatidylinositol 3-kinase inhibitors for cancer.
    Bowles DW; Jimeno A
    Expert Opin Investig Drugs; 2011 Apr; 20(4):507-18. PubMed ID: 21395485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Association for Cancer Research--100th Annual Meeting. HDAC inhibitors, proteasome inhibitors and vascular disrupting agents. 18-22 April 2009, Denver, CO, USA.
    Mitra AP
    IDrugs; 2009 Jun; 12(6):339-41. PubMed ID: 19517310
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment for advanced tumors: SRC reclaims center stage.
    Summy JM; Gallick GE
    Clin Cancer Res; 2006 Mar; 12(5):1398-401. PubMed ID: 16533761
    [No Abstract]   [Full Text] [Related]  

  • 14. CMT-3. CollaGenex.
    Fingleton B
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1460-7. PubMed ID: 14763133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Targets of Active Anticancer Compounds Derived from Marine Sources.
    Song X; Xiong Y; Qi X; Tang W; Dai J; Gu Q; Li J
    Mar Drugs; 2018 May; 16(5):. PubMed ID: 29786660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC inhibitors as potential therapeutic agents for human cancers.
    Trevino JG; Summy JM; Gallick GE
    Mini Rev Med Chem; 2006 Jun; 6(6):681-7. PubMed ID: 16787379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Src continues aging: current and future clinical directions.
    Kopetz S; Shah AN; Gallick GE
    Clin Cancer Res; 2007 Dec; 13(24):7232-6. PubMed ID: 18094400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer.
    Jäger T; Ocker M; Kiesslich T; Neureiter E; Neureiter D
    Expert Opin Investig Drugs; 2017 Feb; 26(2):133-136. PubMed ID: 28004600
    [No Abstract]   [Full Text] [Related]  

  • 19. Implications for Src kinases in hematopoiesis: signal transduction therapeutics.
    Sinha S; Corey SJ
    J Hematother Stem Cell Res; 1999 Oct; 8(5):465-80. PubMed ID: 10791898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proprotein convertase inhibition: Paralyzing the cell's master switches.
    Klein-Szanto AJ; Bassi DE
    Biochem Pharmacol; 2017 Sep; 140():8-15. PubMed ID: 28456517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.